Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity

Proceedings of the National Academy of Sciences of the United States of America

Volumn 114, Issue 5, 2017, Pages E761-E770

  Chamoto, Kenji ^a   Chowdhury, Partha S ^a   Kumar, Alok ^a   Sonomura, Kazuhiro ^a,b   Matsuda, Fumihiko ^a   Fagarasan, Sidonia ^c   Honjo, Tasuku ^a  

^a KYOTO UNIVERSITY   (Japan)

^b SHIMADZU CORPORATION   (Japan)

^c Institute of Physical and Chemical Research   (Japan)

Author keywords

Cancer immunotherapy; Immune metabolism; Mitochondria; PD 1; PGC 1

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; CYCLIC AMP DEPENDENT PROTEIN KINASE; HERMES ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PROGRAMMED DEATH 1 RECEPTOR; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR NRF2; TRANSCRIPTION FACTOR T BET; 4,6-DIMORPHOLINO-N-(4-NITROPHENYL)-1,3,5-TRIAZIN-2-AMINE; 6,7 DIHYDRO 4 HYDROXY 3 (2' HYDROXY 1,1' BIPHENYL 4 YL) 6 OXOTHIENO[2,3 B]PYRIDINE 5 CARBONITRILE; CYTOKINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MONOCLONAL ANTIBODY; MORPHOLINE DERIVATIVE; MTOR PROTEIN, MOUSE; PPARGC1A PROTEIN, MOUSE; PYRONE DERIVATIVE; TARGET OF RAPAMYCIN KINASE; THIOPHENE DERIVATIVE; TRIAZINE DERIVATIVE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL ACTIVITY; CELL EXPANSION; CELL MIGRATION; CONFERENCE PAPER; EFFECTOR CELL; ENZYME PHOSPHORYLATION; HUMAN; LYMPHOCYTE FUNCTION; MITOCHONDRION; MOUSE; NONHUMAN; PRECURSOR; PRIORITY JOURNAL; T LYMPHOCYTE; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; C57BL MOUSE; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECTS; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; LYMPH NODE; METABOLISM; NEOPLASM; OXYGEN CONSUMPTION; TUMOR CELL LINE;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; CYTOKINES; LYMPH NODES; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MITOCHONDRIA; MORPHOLINES; NEOPLASMS; OXYGEN CONSUMPTION; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA COACTIVATOR 1-ALPHA; PROGRAMMED CELL DEATH 1 RECEPTOR; PYRONES; REACTIVE OXYGEN SPECIES; T-LYMPHOCYTES, CYTOTOXIC; THIOPHENES; TOR SERINE-THREONINE KINASES; TRIAZINES;

EID: 85011295946     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1620433114     Document Type: Article

References (63)

1. Couzin-Frankel J (2013) Breakthrough of the year 2013. Cancer immunotherapy. Science 342(6165):1432-1433.
2. Topalian SL, Drake CG, Pardoll DM (2015) Immune checkpoint blockade: A common denominator approach to cancer therapy. Cancer Cell 27(4):450-461.
3. Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T (2013) A rheostat for immune responses: The unique properties of PD-1 and their advantages for clinical application. Nat Immunol 14(12):1212-1218.
4. Brahmer JR, et al. (2010) Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28(19):3167-3175.
5. Zou W, Wolchok JD, Chen L (2016) PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med 8(328):328rv4.
6. Robert C, et al. (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372(4):320-330.
7. Mahoney KM, Rennert PD, Freeman GJ (2015) Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov 14(8):561-584.
8. Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo T (2001) PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domaincontaining tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci USA 98(24): 13866-13871.
9. Li J, et al. (2015) PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment. Cancer Res 75(3):508-518.
10. Nishimura H, Nose M, Hiai H, Minato N, Honjo T (1999) Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11(2):141-151.
11. Nishimura H, et al. (2001) Autoimmune dilated cardiomyopathy in PD-1 receptordeficient mice. Science 291(5502):319-322.
12. Okazaki T, et al. (2003) Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med 9(12):1477-1483.
13. Iwai Y, et al. (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 99(19):12293-12297.
14. Iwai Y, Terawaki S, Ikegawa M, Okazaki T, Honjo T (2003) PD-1 inhibits antiviral immunity at the effector phase in the liver. J Exp Med 198(1):39-50.
15. Topalian SL, et al. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443-2454.
16. Brahmer JR, et al. (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366(26):2455-2465.
17. van der Windt GJ, et al. (2013) CD8 memory T cells have a bioenergetic advantage that underlies their rapid recall ability. Proc Natl Acad Sci USA 110(35):14336-14341.
18. Sena LA, et al. (2013) Mitochondria are required for antigen-specific T cell activation through reactive oxygen species signaling. Immunity 38(2):225-236.
19. Uzhachenko R, Shanker A, Yarbrough WG, Ivanova AV (2015) Mitochondria, calcium, and tumor suppressor Fus1: At the crossroad of cancer, inflammation, and autoimmunity. Oncotarget 6(25):20754-20772.
20. Turrens JF (2003) Mitochondrial formation of reactive oxygen species. J Physiol 552(Pt 2): 335-344.
21. Weinberg SE, Sena LA, Chandel NS (2015) Mitochondria in the regulation of innate and adaptive immunity. Immunity 42(3):406-417.
22. Tumeh PC, et al. (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515(7528):568-571.
23. McGranahan N, et al. (2016) Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351(6280):1463-1469.
24. Gubin MM, et al. (2014) Checkpoint blockade cancer immunotherapy targets tumourspecific mutant antigens. Nature 515(7528):577-581.
25. Jang KJ, et al. (2015) Mitochondrial function provides instructive signals for activation-induced B-cell fates. Nat Commun 6:6750.
26. van der Windt GJW, Chang C-H, Pearce EL (2016) Measuring bioenergetics in T cells using a Seahorse Extracellular Flux Analyzer. Curr Protoc Immunol 113:16B.1-16B.14.
27. Trachootham D, Alexandre J, Huang P (2009) Targeting cancer cells by ROS-mediated mechanisms: A radical therapeutic approach? Nat Rev Drug Discov 8(7):579-591.
28. Dixit D, Ghildiyal R, Anto NP, Sen E (2014) Chaetocin-induced ROS-mediated apoptosis involves ATM-YAP1 axis and JNK-dependent inhibition of glucose metabolism. Cell Death Dis 5:e1212.
29. Gloerich J, et al. (2005) A phytol-enriched diet induces changes in fatty acid metabolism in mice both via PPARalpha-dependent and-independent pathways. J Lipid Res 46(4):716-726.
30. Krauss S, Zhang CY, Lowell BB (2005) The mitochondrial uncoupling-protein homologues. Nat Rev Mol Cell Biol 6(3):248-261.
31. Brand MD (2000) Uncoupling to survive? The role of mitochondrial inefficiency in ageing. Exp Gerontol 35(6-7):811-820.
32. Olsson M, Wilson M, Uller T, Isaksson C (2009) Free radicals run in lizard families without (and perhaps with) mitochondrial uncoupling. Biol Lett 5(3):345-346.
33. Han YH, Kim SH, Kim SZ, Park WH (2009) Carbonyl cyanide p-(trifluoromethoxy) phenylhydrazone (FCCP) as an O2(-) generator induces apoptosis via the depletion of intracellular GSH contents in Calu-6 cells. Lung Cancer 63(2):201-209.
34. Friederich-Persson M, et al. (2013) Kidney hypoxia, attributable to increased oxygen consumption, induces nephropathy independently of hyperglycemia and oxidative stress. Hypertension 62(5):914-919.
35. Rohas LM, et al. (2007) A fundamental system of cellular energy homeostasis regulated by PGC-1alpha. Proc Natl Acad Sci USA 104(19):7933-7938.
36. Chi H (2012) Regulation and function of mTOR signalling in T cell fate decisions. Nat Rev Immunol 12(5):325-338.
37. Araki K, Ahmed R (2013) AMPK: A metabolic switch for CD8+ T-cell memory. Eur J Immunol 43(4):878-881.
38. Buck MD, O'Sullivan D, Pearce EL (2015) T cell metabolism drives immunity. J Exp Med 212(9):1345-1360.
39. Siska PJ, Rathmell JC (2015) T cell metabolic fitness in antitumor immunity. Trends Immunol 36(4):257-264.
40. Finlay D, Cantrell DA (2011) Metabolism, migration and memory in cytotoxic T cells. Nat Rev Immunol 11(2):109-117.
41. Blagih J, et al. (2015) The energy sensor AMPK regulates T cell metabolic adaptation and effector responses in vivo. Immunity 42(1):41-54.
42. Kimball SR, Do AN, Kutzler L, Cavener DR, Jefferson LS (2008) Rapid turnover of the mTOR complex 1 (mTORC1) repressor REDD1 and activation of mTORC1 signaling following inhibition of protein synthesis. J Biol Chem 283(6):3465-3475.
43. Morita M, et al. (2015) mTOR coordinates protein synthesis, mitochondrial activity and proliferation. Cell Cycle 14(4):473-480.
44. Ventura-Clapier R, Garnier A, Veksler V (2008) Transcriptional control of mitochondrial biogenesis: The central role of PGC-1alpha. Cardiovasc Res 79(2):208-217.
45. Sano M, et al. (2007) Intramolecular control of protein stability, subnuclear compartmentalization, and coactivator function of peroxisome proliferator-activated receptor gamma coactivator 1alpha. J Biol Chem 282(35):25970-25980.
46. Yu Z, et al. (2011) Oltipraz upregulates the nuclear factor (erythroid-derived 2)-like 2 [corrected](NRF2) antioxidant system and prevents insulin resistance and obesity induced by a high-fat diet in C57BL/6J mice. Diabetologia 54(4):922-934.
47. Tenenbaum A, Fisman EZ (2012) Balanced pan-PPAR activator bezafibrate in combination with statin: Comprehensive lipids control and diabetes prevention? Cardiovasc Diabetol 11:140.
48. Rao RR, Li Q, Gubbels Bupp MR, Shrikant PA (2012) Transcription factor Foxo1 represses T-bet-mediated effector functions and promotes memory CD8(+) T cell differentiation. Immunity 36(3):374-387.
49. Cunningham JT, et al. (2007) mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. Nature 450(7170):736-740.
50. Toyama EQ, et al. (2016) AMP-activated protein kinase mediates mitochondrial fission in response to energy stress. Science 351(6270):275-281.
51. Inoki K, Kim J, Guan KL (2012) AMPK and mTOR in cellular energy homeostasis and drug targets. Annu Rev Pharmacol Toxicol 52:381-400.
52. Berrien-Elliott MM, et al. (2015) Checkpoint blockade immunotherapy relies on T-bet but not Eomes to induce effector function in tumor-infiltrating CD8+ T cells. Cancer Immunol Res 3(2):116-124.
53. Paley MA, et al. (2012) Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection. Science 338(6111):1220-1225.
54. Staron MM, et al. (2014) The transcription factor FoxO1 sustains expression of the inhibitory receptor PD-1 and survival of antiviral CD8(+) T cells during chronic infection. Immunity 41(5):802-814.
55. Bengsch B, et al. (2016) Bioenergetic insufficiencies due to metabolic alterations regulated by the inhibitory receptor PD-1 are an early driver of CD8(+) T cell exhaustion. Immunity 45(2):358-373.
56. Scharping NE, et al. (2016) The tumor microenvironment represses T cell mitochondrial biogenesis to drive intratumoral T cell metabolic insufficiency and dysfunction. Immunity 45(2):374-388.
57. Spranger S, et al. (2014) Mechanism of tumor rejection with doublets of CTLA-4, PD-1/ PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. J Immunother Cancer 2:3.
58. Kinjyo I, et al. (2015) Real-time tracking of cell cycle progression during CD8+ effector and memory T-cell differentiation. Nat Commun 6:6301.
59. Opferman JT, Ober BT, Ashton-Rickardt PG (1999) Linear differentiation of cytotoxic effectors into memory T lymphocytes. Science 283(5408):1745-1748.
60. Bammler TK, Slone DH, Eaton DL (2000) Effects of dietary oltipraz and ethoxyquin on aflatoxin B1 biotransformation in non-human primates. Toxicol Sci 54(1):30-41.
61. Markt P, Schuster D, Kirchmair J, Laggner C, Langer T (2007) Pharmacophore modeling and parallel screening for PPAR ligands. J Comput Aided Mol Des 21(10-11): 575-590.
62. Nishimura H, Minato N, Nakano T, Honjo T (1998) Immunological studies on PD-1 deficient mice: Implication of PD-1 as a negative regulator for B cell responses. Int Immunol 10(10):1563-1572.
63. Trapnell C, Pachter L, Salzberg SL (2009) TopHat: Discovering splice junctions with RNA-seq. Bioinformatics 25(9):1105-1111.